JHL Biosimilar Pipeline

Molecule
Potential Indication / Disease Area
Description
Status

JHL1266
(Biosimilar Denosumab)

Osteoporosis, Bone CancerBone Loss, Bone pain, Fracture Bone, Spinal Cord Compression, Bone destruction, Giant cell tumor of the bone, High risk of fracture, Refractory Hypercalcemia of malignancy

A novel, fully human IgG2 monoclonal antibody specific to receptor activator of nuclear factor kappa-B ligand (RANKL)

Pre-Clinical Stage (Selecting Clone in progress)

Click to read more on JHL1266 (Denosumab)

JHL1266 is a proposed biosimilar to denosumab, which is marketed by Amgen under the trade name Prolia® and Xgeva®.

Denosumab is a monoclonal antibody therapy used for treatment of a range of osteoporosis, Colorectal cancer (CRC).

JHL1152 
(Biosimilar Ipilimumab)

Late-Stage Melanoma

A cytotoxic T-lymphocyte antigen 4 (CTLA-4)-blocking antibody.

Pre-Clinical Stage (Selecting Clone in progress)

Click to read more on JHL1152 (Ipilimumab)

JHL1152 is a proposed biosimilar to ipilimumab, a cytotoxic T-lymphocyte antigen 4 (CTLA-4)-blocking antibody.

JHL1255 
(Biosimilar Ustekinumab)

Psoriasis, Crohn’s Disease

Human monoclonal antibody that is directed against interleukin 12 and interleukin 23

Pre-Clinical Stage (Selecting Clone in progress)

Click to read more on JHL1255 (Ustekinumab)

JHL1255 is a proposed biosimilar to ustekinumab, a human monoclonal antibody that is directed against interleukin 12 and interleukin 23, naturally occurring proteins that regulate the immune system and immune-mediated inflammatory disorders.

JHL1178 
(Biosimilar Ramucirumab)

NSCLC, GC,CRC

Human IgG1 that binds to VEGFR2

Pre-Clinical Stage (Selecting Clone in progress)

Click to read more on JHL1178 (Ramucirumab)

JHL1178 is a proposed biosimilar to ramucirumab, a human IgG1 that binds to VEGFR2, which in turn blocks the natural ligands secreted by tumors, therefore can inhibit tumor angiogenesis.

Interested in working with us?

JHL is open for partnerships and license agreements for its biosimilar assets worldwide. We can offer you access to our expertise in process development, manufacturing and regulatory management.